Pharmaceuticals News & Press Release Distribution

Excelra Partners with HotSpot Therapeutics to Enhance Allosteric Drug Discovery Efforts

HYDERABAD, India and BOSTON, May 25, 2022 /PRNewswire/ -- Excelra, a leading global data and digital insights organization, today announced a partnership with HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for th...

2022-05-25 23:04 4458

The Centre for Probe Development and Commercialization expands into Asia and executes a development, manufacturing, and clinical supply agreement for 177Lu-PSMA (DGUL) With South Korea-based CellBion

HAMILTON, ON, May 25, 2022 /PRNewswire/ -- The Centre for Probe Development and Commercialization (CPDC) is pleased to announce the initiation of a development, manufacturing, and supply agreement withCellBion for Lu-177-radiolabelled PSMA (DGUL) therapeutic agent. Under the terms of the agreeme...

2022-05-25 21:00 2062

Seegene unveils '$12 PCR testing' initiative to help end COVID-19 pandemic

Includes asymptomatic testing at community-based facilities to prevent widespread transmissions Regular testing for COVID-19, flu, RSV crucial for staying safe as anti-virus restrictions are eased PCR tests will be priced affordably, made possible through Seegene's 20 years of expertise "Full ...

2022-05-25 19:00 3145

Harbour BioMed Announces Dosing of First Patient in Phase I Trial of B7H4x4-1BB Bispecific Antibody

CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 25, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announcedthat it has successfully completed the dosing of first patient in phase I trial of B7H4x4-1BB bispecific antibody HBM7008 inAustralia. This study will evaluate ...

2022-05-25 17:42 3078

Brii Biosciences to be Added to MSCI China Small Cap Index

DURHAM, N.C. and BEIJING, May 25, 2022 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) today announced that it will be added to the MSCI China Small Cap Index, effective as ofHong Kong market close on May 31, 2022. ...

2022-05-25 08:00 6455

Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

* Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. * The candidate is intended to be used for the treatment of SARS-CoV-2 and its variants, along with other coronaviruses. * ...

2022-05-25 05:00 3591

Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

ICP DAS - BMP will attend Medical Taiwan Expo 2022 in Taipei

TAIPEI, May 25, 2022 /PRNewswire/ -- ICP DAS - BMP (Biomedical Polymers), a Taiwanese medical TPU (thermoplastic polyurethane) supplier, will exhibit at Medical Taiwan 2022, an international medical, health, and care expo. The Medical Taiwan Expo 2022 will take place at the Taipei Nangang Exhibit...

2022-05-25 01:25 5745

ICP DAS - BMP will attend Medical Taiwan Expo 2022 in Taipei

Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

* Insilico's candidate demonstrated a favorable profile with good in vivo efficacy at low doses, efficient synthesis, and no need for co-administration with Ritonavir. * The candidate is intended to be used for the treatment of SARS-CoV-2 and its variants, along with other coronaviruses. Insi...

2022-05-24 21:00 3768

Travecta Therapeutics Announces In-Person Presentation at 2022 BIO International Convention

SINGAPORE and PRINCETON, N.J., May 24, 2022 /PRNewswire/ -- Travecta Therapeutics, Pte Ltd., a private biopharmaceutical company pioneering transformative treatments for serious neurological conditions by utilizing a natural transport system in the blood-brain barrier ("BBB") as a novel delivery ...

2022-05-24 20:00 3130

New Study Shows Critical Role of 1,5-Anhydroglucitol (1,5-AG) in COVID-19 Pathogenesis by Binding to the COVID-19 Spike Protein

Study Findings Support Data Presented on the GlycoMark Blood Test at the Most RecentADA and AHA Scientific Sessions RALEIGH, N.C., May 24, 2022 /PRNewswire/ -- Precision Diabetes, Inc. A new study recently published inNature Metabolism shows that 1,5-anhydroglucitol (1,5-AG), a glucose-like me...

2022-05-24 19:00 2096

Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis

SHANGHAI, May 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) presented at Digestive Disease Week (DDW) 2022 detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluatin...

2022-05-24 19:00 2545

Everest Medicines' Licensing Partner Pfizer Presents ELEVATE Pivotal Findings Demonstrating Etrasimod's Potentially Best-in-Class Profile in Ulcerative Colitis

SHANGHAI, May 24, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) presented at Digestive Disease Week (DDW) 2022 detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluatin...

2022-05-24 19:00 3627

Pierre Fabre and EORTC open a large Phase III clinical study in the adjuvant setting of stage IIB-C melanoma

* First study conducted in the adjuvant setting with a combination of BRAF and MEK inhibitors in high-risk stage II BRAF V600E/K-mutant cutaneous melanoma * A global partnership between EORTC and Pierre Fabre to advance research in melanoma CASTRES, France and BRUSSELS, May 24, 2022 /PRNewswir...

2022-05-24 14:15 2480

RemeGen to Present Three Studies on Disitamab Vedotin at 2022 ASCO Annual Meeting

YANTAI, China, May 23, 2022 /PRNewswire/ -- RemeGen Co., Ltd. (9995.HK, SHA: 688331), a commercial-stage biotechnology company, today announced that three abstracts for disitamab vedotin (RC48) have been selected for poster discussions by the 2022 American Society of Clinical Oncology (ASCO) Ann...

2022-05-24 10:27 2709

SwipeRx secures US$27 Million in Series B Funding to accelerate growth across Southeast Asia

SINGAPORE, May 24, 2022 /PRNewswire/ -- SwipeRx (formerly mClinica Pharmacy Solutions),Southeast Asia's (SEA) leading platform for pharmacies, announced it has secured a Series B round ofUS$27 million in equity and debt to accelerate growth across SEA. The round was led byIndonesia's MDI Ventures...

2022-05-24 10:00 3240

HistoSonics Announces Agreement with GE Healthcare

HistoSonics Breakthrough Liver Therapy System to Utilize GE's LOGIQ™ E10 for Real-Time Imaging Guidance and Treatment Verification MINNEAPOLIS, May 23, 2022 /PRNewswire/ -- HistoSonics Inc., developer of a completely non-invasive platform using the science of histotripsy, today announced an agre...

2022-05-23 21:00 3711

HistoSonics Announces Agreement with GE Healthcare

Medison Pharma Announces Extension of Multi-territorial Agreement with Immunocore and Expansion into Australia and New Zealand

The latest geographic growth increases Medison's global footprint across 25 countries in four continents, further strengthening its commercial offering PETACH TIKVAH, Israel, May 23, 2022 /PRNewswire/ -- Medison Pharma ("Medison"), a global pharma company focused ...

2022-05-23 20:28 4480

VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone

SHANGHAI, May 23, 2022 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, today announced positive top-line results from its pivotal phase 3 trial, a randomized, open-label, active-controlled trial that compared lonapegsomatropin (TransCo...

2022-05-23 15:57 1744

Antengene Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas

SHANGHAI and HONG KONG, May 23, 2022 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer...

2022-05-23 10:10 3945

Hanmi Fine Chemical Launches 'high-tech CDMO' Business

CDMO business initiated such as mRNA vaccine raw materials·peptides 10 billion KRW invested in Hanmi Fine Chemical facility expansion SEOUL, South Korea, May 22, 2022 /PRNewswire/ -- Hanmi Fine Chemical (hereinafter Hanmi FC) a subsidiary of Hanmi Pharmaceutical Group specializing in APIs(Active...

2022-05-23 08:32 3215